CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性大 B 细胞淋巴瘤的管理：英国血液学会指南
英文原题：Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline.
查看英文原题
Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
复发时间是预测复发性弥漫性大B细胞淋巴瘤结局的最强指标。对于一线化学免疫治疗后12个月内进展的患者，建议二线采用嵌合抗原受体（CAR）T细胞疗法。对于晚期复发患者，建议采用铂类化疗，随后给予大剂量化疗并进行自体干细胞支持。二次复发时，符合条件的患者建议接受CAR-T 细胞或CD3×CD20双特异性抗体治疗。体能状态较差患者还有其他治疗选择。本文还就诊断性免疫组织化学检查、苯达莫司汀使用以及CAR-T 细胞治疗的桥接治疗提出了具体建议。
展开英文摘要原文
Time to progression is the strongest predictor of outcome in relapsed diffuse large B-cell lymphoma. Second-line treatment with chimeric antigen receptor (CAR) T-cell therapy is recommended for patients with progression within 12 months of first-line chemoimmunotherapy. In patients with late relapse, platinum-based chemotherapy followed by high-dose chemotherapy with autologous stem cell rescue is recommended.
In second relapse, CAR T-cell or CD3xCD20 bispecific antibody therapy is recommended in eligible patients. Other treatment options are available for less fit patients. Specific recommendations are made on diagnostic immunohistochemistry, bendamustine use and bridging to CAR T-cell therapy.
论文信息
- 作者
- Chaganti S、Fox CP、Maybury BD、Burton C、Barrington SF、Illidge T、Kalakonda N、Eyre TA
- 第一作者单位
- Centre for Clinical Haematology, University Hospitals Birmingham, Birmingham, United Kingdom.United Kingdom
- 通讯作者单位
- Cancer Sciences Divisions, Centre for Cancer Immunology, University of Southampton, Southampton, United Kingdom.United Kingdom
- 文献类型
- 临床实践指南
- 期刊
- British journal of haematology2025 Jun
- 原文标识
- PubMed 40384597 · DOI 10.1111/bjh.20129